Lori Calvasina, head of US equity strategy at RBC Capital Markets, discusses current stock market sentiment, noting investor nervousness but no signs of panic.

ResMed has been downgraded by RBC Capital Markets, citing challenges anticipated for the company in fiscal year 2027.

RBC Capital has lowered its price target for HawkEye 360 (HAWK), providing reasons for the revised financial assessment of the company.

RBC Capital has increased its price target for Sonida (SNDA), indicating a positive outlook on the company's stock performance.

RBC Capital has increased its price target for Moderna (MRNA), signaling a positive outlook for the pharmaceutical company's stock.

RBC Capital Markets has initiated coverage on NiSource with an Outperform rating, highlighting Indiana as one of the best data center markets in the Midwest.

American Tower (AMT) has received an upgrade to an 'Outperform' rating from RBC Capital.

RBC Capital has lowered its price target for Carvana Co. (CVNA), reflecting a revised outlook on the online used car retailer.

RBC Capital has initiated coverage on Black Stone Minerals (BSM), highlighting the company's exposure to natural gas.

RBC Capital has raised its price target on F5 (FFIV), HSBC on Zoom (ZM), JPMorgan on Old Dominion Freight Line (ODFL), and UBS on J. M. Smucker (SJM). These adjustments indicate increased confidence in the future performance of these companies.

RBC Capital has reaffirmed its 'Outperform' rating for Zillow Group (ZG), signaling a positive outlook on the real estate technology company's stock.

Vertical Research has upgraded Albemarle (ALB) to a bullish rating, while RBC Capital Markets reiterated its Outperform rating for the company.

RBC Capital has raised its price target for Neurocrine Biosciences (NBIX), signaling a positive outlook for the biopharmaceutical company's stock.

According to RBC Capital, Newmont (NEM) is trading at a premium valuation compared to its peers within the gold equities sector. This assessment highlights its strong market position.

RBC Capital has issued an 'Outperform' rating for Magnite, Inc. (MGNI) stock.

RBC Capital has lowered its price target for FactSet (FDS) to $240 while maintaining a Sector Perform rating on the stock.

RBC Capital Markets suggests that Radian's (RDN) acquisition of Inigo could lead to higher earnings growth for the company.

RBC Capital Markets predicts that any potential pullback in the S&P 500 index is likely to be limited to a range of 5% to 10%, offering a cautious outlook on market volatility.

DA Davidson and RBC Capital Markets have adopted a more cautious outlook on Home Depot (HD) after the company's recent earnings announcement.

RBC Capital has reaffirmed its 'Sector Perform' rating for UiPath, Inc. (PATH).

RBC Capital has cut its rating for Wix after the company announced its first-quarter financial results.

RBC Capital and Raymond James have both increased their price targets for energy companies Cenovus Energy and Energy Transfer, respectively.

RBC Capital analysts have increased their price target for Jacobs Solutions (J) shares to $169, reflecting a positive assessment of the company's performance.

BMO Capital has maintained its bullish stance on Linde (LIN), while RBC Capital Markets suggests there is room for upside in the company's guidance.

Scotiabank and RBC Capital have both raised their price targets for Venture Global (VG).

RBC Capital has assigned a "Buy" rating to Wix (WIX), indicating a positive outlook for the company's stock. This recommendation suggests potential for growth for investors.

Citi and RBC Capital analysts have noted improving broadband trends for Comcast (CMCSA), indicating a positive outlook for the company's internet services.

RBC Capital has increased its price target for Astera Labs (ALAB), anticipating a significant boost from the upcoming Amazon Trainium3 AI chips.

RBC Capital has increased its price target for Restaurant Brands International (QSR) stock, citing continued positive momentum for the company.

RBC Capital Markets has upgraded its rating for Unilever (UL) stock from its previous position to 'Sector Perform'. This change reflects a revised outlook on the consumer goods giant's market performa

RBC Capital has shown upward momentum in its price target for LyondellBasell (LYB), indicating a positive outlook for the company.

RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.

RBC Capital Markets has adjusted its price targets for several companies, trimming Procter & Gamble's target due to modest growth while lifting Chevron's target as its commodity view improves.

RBC Capital has lowered its price target for Autoliv from $141 to $137 and for Dauch Corporation from $10 to $9. These adjustments reflect updated financial outlooks for both companies.

RBC Capital has reiterated its 'Outperform' rating for Wave Life Sciences (WVE), indicating a continued positive outlook on the biotechnology company's stock.

RBC Capital has increased its price target for Nutrien (NTR) in anticipation of the company's first-quarter earnings report. The adjustment is attributed to strong fertilizer prices, signaling positive expectations for Nutrien's performance.

Baird, a financial services firm, has reduced its price target for Nyxoah SA (NYXH) shares from $5.87 to $4.62. This adjustment reflects a revised outlook on the company's financial performance or market conditions.

RBC Capital attributes FactSet's strong second-quarter performance to competitive wins and increased pricing strategies. This analysis follows FactSet's reported Q2 beat.

BMO Capital has reduced its price target for BioNTech SE (BNTX) from $143 to $128.

RBC Capital has reduced its price target on Graphic Packaging (GPK) from $13 to $10, reflecting a revised outlook for the company's stock.

RBC Capital Markets has increased its stock price target for Canadian National (CN) for the year 2027, indicating a positive outlook for the railway company.

RBC Capital has reduced its price target for FactSet Research Systems (FDS) from $320 to $243.

RBC Capital has reiterated its 'Sector Perform' rating for Advanced Micro Devices (AMD) stock.

RBC Capital Markets has identified weaknesses in the housing market as a significant risk factor for Installed Building Products, Inc. (IBP).

RBC Capital has increased its price target for Nuvation Bio (NUVB) from $12 to $13, citing reasons for the upward adjustment.

RBC Capital and Bernstein have both raised their price targets for Eaton Corporation plc (ETN), reflecting a positive outlook for the company's stock.

RBC Capital suggests that Ollie's Bargain Outlet faces a 'noisy' first quarter, but its 2026 prospects are underestimated by investors.

RBC Capital has reduced its price target for Broadcom Inc. (AVGO) from $370 to $340, citing specific reasons for the adjustment.

Wix.com price target lowered to $112 from $155 at RBC Capital  The Globe and Mail

RBC Capital has raised its price target for HSBC Holdings (HSBC) while maintaining a 'Hold' rating on the stock.

Morgan Stanley and RBC Capital both raise their target forecasts for Kinder Morgan.

RBC Capital Markets has issued a note indicating that CareTrust REIT, Inc. (CTRE) is well-positioned, even amid increased general and administrative expenses and investment timing considerations.

RBC Capital has reiterated its 'Hold' rating on Rio Tinto Group (RIO), indicating a neutral outlook on the mining company's stock.

RBC Capital Markets has increased its price objective for The Bank of Nova Scotia (BNS), citing an improving credit outlook for the bank.

RBC Capital has expressed a favorable view on Voya Financial's (VOYA) fourth-quarter performance, suggesting positive analyst sentiment.

RBC Capital has increased its price target for Home Depot shares from $363 to $377.

RBC Capital projects that Merck (MRK) will return to growth sooner than market expectations.

Ares Management Corporation to Present at the 2026 RBC Capital Markets Global Financial Institutions Conference  The Globe and Mail

RBC Capital has reiterated its rating on Fiserv, Inc. (FISV) after the company exceeded its Q4 earnings expectations.

RBC Capital has reduced its price target on Autodesk, Inc. (ADSK) to $340 while maintaining an Outperform rating.

Several financial institutions have updated their price targets for a range of companies, including CytomX Therapeutics, Upwork, Coursera, Tripadvisor, and The Wendy's Company, while maintaining various ratings.

RBC Capital Markets has raised its rating on Equinor, citing a more supportive market environment that provides the company with breathing room.

RBC Capital has reaffirmed its Outperform rating for Verastem (VSTM), indicating continued confidence in the company's stock performance. This reiteration suggests a positive outlook from the financial institution.

RBC Capital has reduced its price target for Nuvation Bio (NUVB) in its Q2 preview, indicating a revised outlook for the biotechnology company.

RBC Capital has downgraded AVAV stock, with the article explaining the reasons behind this investment rating change.

RBC Capital has increased its price target on Rackspace Technology (RXT), citing specific reasons for its optimistic outlook. This adjustment reflects the firm's updated analysis of the company's financial performance and market position.

RBC Capital has reportedly increased its price target for Cameco Corporation (CCJ).

RBC Capital has maintained its Outperform rating on Carvana (CVNA), and William Blair has kept its Outperform rating on Medline (MDLN) following a warehouse fire.

RBC Capital has affirmed its 'Sector Perform' rating on Regeneron (REGN), providing reasons for its continued assessment of the biotechnology company.

RBC Capital Markets highlights that Varonis Systems' emphasis on data security and governance is becoming increasingly crucial in the evolving landscape of the artificial intelligence era.

RBC Capital has identified potential demand and inflation risks for Campbell's (CPB), impacting its market outlook.

RBC Capital has maintained its 'Outperform' rating on Equinox (EQX), signaling continued confidence in the real estate investment trust's stock performance.

RBC Capital Markets has established the highest price target for Astera Labs (ALAB) stock, with an accompanying analysis on how investors can capitalize on the memory trade.

RBC Capital has lifted its price target for The Toronto-Dominion Bank (TD), suggesting an improved valuation for the financial institution.

RBC Capital has reiterated its 'Outperform' rating and an $810 price target for Meta Platforms (META), citing an explosion in AI-enabled entrepreneurialism as a key driver.

RBC Capital Markets has cut its rating for Rio Tinto to 'Sell' equivalent, citing expectations for a continued decline in iron ore prices.

RBC Capital has begun its coverage of Avantor (AVTR) by assigning a 'Sector Perform' rating to the company's stock.

RBC Capital and UBS have maintained their bullish outlook on Chevron following the company's robust first-quarter financial performance.

RBC Capital has announced that it is resuming its coverage of Danaher Corporation (DHR), a move that often signals renewed analyst interest in the company.

RBC Capital has increased its price target for Enbridge (ENB), indicating a revised outlook on the company's stock valuation.

RBC Capital has increased its price target for Banco Santander (SAN) and reiterated an 'Outperform' rating for the bank's stock.

RBC Capital Markets has reduced its price target for IBM but continues to hold a bullish rating on the stock.

Mosaic, a leading producer of phosphate and potash, received an upgrade from RBC Capital, which expressed optimism that challenges in the phosphate market would not persist indefinitely.

RBC Capital has slightly reduced its price target for McDonald's (MCD) despite the company reporting better-than-expected first-quarter results.

RBC Capital reports that Target's turnaround strategies are beginning to show early signs of progress.

RBC Capital has increased its price target for BioCryst Pharmaceuticals (BCRX) as part of its preview of Q1 2026 results in the biotech sector. This adjustment reflects RBC Capital's updated outlook on the company's financial prospects.

RBC Capital has expressed caution regarding Wingstop (WING) shares, citing soft same-store sales trends as a concern for the company's performance.

RBC Capital Markets has maintained its Outperform rating on Linde plc (LIN), indicating continued confidence in the company's financial performance and stock potential.

RBC Capital Markets has slightly trimmed its price target for ACADIA Pharmaceuticals, citing seasonal biotech headwinds. The firm also cut its price target for Galapagos NV to $28, while maintaining a Sector Perform rating ahead of its Q1 earnings.

RBC Capital has issued a bullish outlook on PPG Industries (PPG), increasing its price target for the company's stock.

RBC Capital has adjusted its investment position on Unilever, moving away from its previous bearish outlook on the consumer goods giant.

RBC Capital Markets has adjusted its outlook for Becton Dickinson (BDX), trimming its estimates despite stable demand in the MedTech sector.

RBC Capital has reiterated its Outperform rating for ServiceNow (NOW), indicating continued confidence in the company's stock performance.

RBC Capital has adjusted its price target for Ford Motor Company shares, lowering it from $12 to $11.

RBC Capital Markets has upgraded its rating for Asana (ASAN) stock, setting a new price target of $7.

JPMorgan, UBS, and RBC Capital have all increased their price targets for Venture Global (VG), signaling positive outlooks for the company.

RBC Capital has reiterated its "Sector Perform" rating for FactSet Research Systems (FDS).

RBC Capital has increased its price target for Kinder Morgan (KMI) by $3, reflecting an updated outlook on the company's stock.

RBC Capital has adjusted its price target for Exelixis (EXEL) stock downwards to $43.

RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.

RBC Capital has upgraded Kinross Gold (KGC) stock to Outperform from Sector Perform.

RBC Capital Markets has identified Revolution, Xenon, and Arrowhead as leading candidates for potential takeovers, according to a recent report.

RBC Capital Markets has set a price target of $45 for Kinross Gold (KGC), outlining the conditions required for the stock to reach this valuation.

RBC Capital has raised its price target for Canadian Natural Resources (CNQ), citing strong leadership and shareholder alignment as key factors.

RBC Capital Markets has reiterated its Outperform rating for Nike (NKE), indicating a positive outlook and seeing a clear path to growth for the sportswear giant.

RBC Capital Markets has lowered the price target for Sweetgreen, Inc. (SG) due to a same-store sales outlook that is trailing behind consensus estimates.

RBC Capital has raised its price target for Cheniere Energy Partners shares from $58 to $62.

RBC Capital has raised its price target on Primo Brands Corporation (PRMB) to $29 and maintained an Outperform rating.

RBC Capital lifts CubeSmart's target, Morgan Stanley boosts Fifth Third Bancorp's target, and Morgan Stanley also raises Huntington Bancshares' target, citing banking sector tailwinds.

RBC Capital has begun coverage on KKR & Co. Inc. (KKR) with an 'Outperform' rating.

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.

Several financial firms, including Morgan Stanley, Truist, RBC Capital, Goldman Sachs, and Scotiabank, have updated their price targets and ratings for companies like Edison International, Vulcan Materials, Global Payments, Insulet, Quanta Services, A. O. Smith, FirstEnergy, and Targa Resources.

RBC Capital initiates coverage on Bristol Myers (BMY) with a $60 target, noting the depth of its late-stage pipeline.

RBC Capital Markets has upgraded its rating for pharmaceutical company AbbVie to 'outperform,' citing expectations for durable growth.

RBC Capital analysts have suggested that Eagle Materials could be worth more if split into two separate entities, according to a new analysis.

RBC Capital suggests that a shift in tariff policy is unlikely to negatively impact U.S. stocks, offering an analysis of the economic outlook.

RBC Capital has increased its price target for Prologis (PLD) due to an improved outlook for industrial real estate.

Several financial institutions, including Stifel, Scotiabank, and Jefferies, have issued updated price targets and ratings for various companies. These reports reflect analysts' current outlooks on stock performance and investment recommendations.

RBC Capital has downgraded Northern Trust's stock rating to Hold-equivalent following the company's second-quarter earnings report.

RBC Capital has reiterated its Sector Perform rating for PepsiCo (PEP) stock.

According to RBC Capital Markets' Frances Donald, underlying inflation pressures persist, casting a shadow over the Federal Reserve's economic outlook and policy decisions.

Several financial institutions, including BofA, RBC Capital, Bernstein, Morgan Stanley, and Truist, have increased their price targets for various companies. These companies include Amazon.com, Tesla, ASML Holding, Lam Research, KLA, and Amgen.

RBC Capital holds a bullish view on Opus Genetics (IRD), citing limited competition and a de-risked operational setup as key factors.

RBC Capital Markets has initiated coverage on Centene (CNC), expressing a positive outlook and suggesting that the company's challenges from 2025 are now behind it.

RBC Capital Markets has begun its coverage of GE HealthCare Technologies Inc. (GEHC), indicating new analyst attention on the company's stock.

Following a strong quarterly earnings report, RBC Capital and Freedom Broker have both increased their price targets for Deere (DE) stock.

RBC Capital has significantly increased its price target for Micron Technology (MU) by $675, explaining the rationale behind this substantial revision. This reflects a bullish sentiment regarding the memory and storage solutions provider.

RBC Capital sees long-term upside for Kinetik Holdings (KNTK) and has consequently raised its price objective for the company.

According to RBC Capital, SSR Mining (SSRM) is currently trading at a discount compared to its peers, despite generating higher free cash flow.

RBC Capital reports that Nike's business turnaround is progressing slower than anticipated, indicating the company is still struggling to gain momentum.

RBC Capital has downgraded its rating for Taylor Morrison Home Corp. to Sector Perform.

RBC Capital has increased its price target for Albemarle (ALB) to $257, while reiterating an 'Outperform' rating on the stock. This indicates a continued positive outlook from the firm for the chemical company.

RBC Capital has reiterated its bullish outlook on Cloudflare (NET), providing analysis on the company's performance and future prospects.

RBC Capital Markets has increased its price target for Marvell Technology stock, citing strong performance and future growth prospects. This adjustment reflects a positive outlook from the investment bank.

RBC Capital has reaffirmed its 'Outperform' rating on Emerson Electric (EMR), maintaining a positive outlook despite economic headwinds from the Middle East.

RBC Capital has trimmed the price target for Lowe’s Companies (LOW) by $32. This adjustment reflects a revised valuation for the home improvement retailer.

RBC Capital has increased its price target for TC Energy (TRP), reflecting a revised valuation for the energy infrastructure company.

RBC Capital suggests Snowflake (SNOW) is likely to see Q1 upside, citing strong checks and increasing adoption of its Cortex Code.

RBC Capital Markets upgraded an unnamed steakhouse chain to outperform, citing increased restaurant traffic and declining beef prices as positive indicators for the sector.

Financial analysts have updated their price targets for two companies: Roth Capital raised its target for Coeur Mining, while RBC Capital lowered its target for Kratos Defense & Security Solutions, Inc. RBC Capital maintained an "Outperform" rating for Kratos.

RBC Capital has lifted its price target for CG Oncology (CGON), citing PIVOT-006 as a complex catalyst, and also raised its price target for Acadia Healthcare Company (ACHC) following its Q1 earnings beat.

RBC Capital notes that Church & Dwight has reported an impressive financial quarter.

RBC Capital has raised its price target for Barclays PLC (BCS) following the release of the bank's first-quarter financial results.

RBC Capital Markets has maintained its 'Underperform' rating for 3M (MMM), indicating a belief that the company has limited upside potential.

According to RBC Capital, Shopify is projected to continue growing at a faster rate than the overall U.S. e-commerce market, indicating strong performance for the platform.

RBC Capital has reiterated its positive outlook on Artisan Partners Asset Management (APAM) in anticipation of the company's first-quarter earnings report.

RBC Capital has maintained its Outperform rating on Shopify (SHOP), citing a strong growth outlook for the company.

RBC Capital Markets has increased its price target for Vertex Pharmaceuticals (VRTX) as it updates its outlook for the biotech sector. This reflects a positive analyst sentiment towards the company.

RBC Capital has raised its price target for Dow (DOW) to $47, indicating a more positive outlook on the company's stock.

RBC Capital has reaffirmed its 'Outperform' rating for Adobe (ADBE) stock, indicating continued confidence in the company's performance.

RBC Capital Markets has downgraded the ratings for oilfield services companies NOV and Trican Well Services.

Morgan Stanley and RBC Capital have both increased their price targets for CF Industries, citing robust fertilizer prices as the primary reason.

RBC Capital Markets has reduced its price target for UBS while simultaneously adjusting its assumptions regarding the bank's Assets Under Management (AUM).

RBC Capital Markets has downgraded Ivanhoe Mines' stock rating, citing expectations of materially lower near-term production for the mining company.

RBC Capital has increased its price target for Enterprise Products Partners (EPD) to $42, indicating a positive outlook for the company's stock.

RBC Capital Markets has initiated coverage of Sonida Senior Living with a 'Buy-equivalent' rating.

RBC Capital Markets has maintained its Outperform rating on Union Pacific (UNP), while also flagging higher Q1 EPS and potential approval risks for the railway company.

JPMorgan has increased its price target for Edison International (EIX) from $66 to $74, reflecting a positive adjustment in its valuation of the utility holding company.

Investment firms RBC Capital and Jefferies have reiterated their bullish ratings on Microsoft (MSFT), signaling continued confidence in the technology giant's stock performance.

Lofty investor expectations for growth and a balanced risk-reward ratio make shares of Starbucks less compelling, according to RBC Capital Markets.

RBC Capital has reiterated its 'Outperform' rating on Enbridge Inc. (ENB), signaling continued confidence in the company's stock performance.

RBC Capital has increased its price target for APA, citing strong oil prices and positive earnings momentum as key factors supporting the company's shares.

RBC Capital Markets has raised its price target for Broadcom (AVGO), citing bullish commentary regarding the company's financial outlook for fiscal year 2027.

RBC Capital has lowered its price target on Autodesk, Inc. (ADSK) stock, reflecting a revised outlook on the design software company.

RBC Capital has maintained its bullish outlook on TPG (TPG).

RBC Capital has lowered its price target for Viridian Therapeutics, Inc. (VRDN) to $42, while still maintaining an Outperform rating on the stock.

RBC Capital has downgraded Clearwater Analytics Holdings, Inc. (CWAN) to Sector Perform and lowered its price target to $24.55.

RBC Capital has lowered its target price on Fidelity National Information Services (FIS) to $69, following a slight miss in its fourth-quarter earnings.

RBC Capital has reduced its price target for Clarivate Plc (CLVT) after the company released its Q4 2025 financial results.

Multiple financial institutions have updated their price targets and ratings for various companies, reflecting new outlooks on their performance and market conditions.

RBC Capital Markets has reduced its price target for Leidos Holdings, Inc. (LDOS) from $230 to $215, citing a service-focused valuation.

RBC Capital initiates coverage on Pfizer (PFE) with a $25 target, highlighting structural revenue headwinds.

Ares Management Corporation is scheduled to present at the 2026 RBC Capital Markets Global Financial Institutions Conference, likely to discuss its financial performance and outlook.

RBC Capital has increased its price outlook for Lowe's (LOW) following strong performance trends observed in January.

RBC Capital Markets has downgraded Imperial Oil, citing that the company's valuation has become 'stretched' following several years of strong stock performance.

RBC Capital has lowered its price target for Figma, Inc. (FIG) to $31 while maintaining a Sector Perform rating on the stock.

Analysts are bullish on several biotech companies, including GH Research, Cybin D/B/A Helus Pharma, and COMPASS Pathways, following a psychedelics symposium and positive model updates, with Baird lowering Bright Minds Biosciences' price target but maintaining an Outperform rating.

RBC Capital has lowered its price target for Zeta Global Holdings (ZETA) to $27, indicating a revised outlook for the company's stock.